title: Advances in molecular targets and chemotherapy of tuberculosis.
abstract: The need for newer, effective drugs with different modes of action against tuberculosis is great, despite the numerous drugs in clinical use and the development of Bacilli Calmette-Guerin (BCG) vaccine. Three major goals should be considered in the development of new antituberculosis drugs: 1) they should be fast acting to reduce the long duration of treatment, thereby avoiding drug toxicity; 2) they should be active against both sensitive and resistant strains of tubercle bacilli; and 3) they should possess significant activity against dormant bacilli, which represent the stage affecting one-third of the world's tuberculosis patients. This review provides an overview of important current drugs, novel targets for the development of antituberculosis agents and future drug candidates.
authors.affiliation: Medical Chemistry Division, Central Drug Research Institute, Lucknow, India.
authors.forename: Seema
authors.initials: S
authors.lastname: Kumari
authors.forename: Vishnu Ji
authors.initials: VJ
authors.lastname: Ram
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends*; D006801:Humans; D014376:Tuberculosis / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000995:Antitubercular Agents